Japan fully approves first biosimilar G-CSF but price process means launch delay
This article was originally published in Scrip
Japan has wasted no time issuing a formal approval for its first biosimilar version of the recombinant granulocyte colony-stimulating factor (G-CSF) filgrastim, granting full regulatory clearance to a product co-developed by Mochida and Fuji Pharma.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.